We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Fluxion Receives $1.2M NIH Grant for the Development of Drug Discovery Platform

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Fluxion Biosciences has announced that it has received a $1.2 million NIH grant for the development of a multiplexed single-cell electroporation system. The Phase II SBIR grant continues the successful development that was funded by NIH as part of a Phase I project completed in 2006.

The newly awarded grant will further the development of Fluxion's intracellular delivery platform. Fluxion is developing a benchtop workstation capable of selecting, trapping, and delivering biological reagents inside individual cells in a highly controlled manner.

Applications for this system include siRNA delivery, protein pathway mapping, and stem cell research. The specific goal of this research grant is the development of a high throughput prototype capable of combining electroporation for intracellular delivery with integrated functional cell analysis.

"We are excited to receive this NIH grant for the continued development of our single-cell electroporation technology," said Cristian Ionescu-Zanetti, Ph.D., co-founder and Chief Technology Officer.

"The ability to carefully control delivery of siRNA, proteins, and other reagents to individual cells offers significant potential to aid research in a number of critical areas, including systems biology research and drug discovery."